F-star Therapeutics CEO Eliot Forster at EUBIO22 (Rachel Kiki for Endpoints News)

In yet an­oth­er de­lay for the F-star buy­out, CFIUS ex­tends re­view of 'na­tion­al se­cu­ri­ty risks'

F-star Ther­a­peu­tics $FSTX has been forced to ex­tend its long streak of de­lays for the pro­posed takeover deal by Chi­na’s Sino Bio­pharm, rais­ing the risk the buy­out may not get a green light as a US com­mit­tee tasked with re­view­ing for­eign in­vest­ments rais­es “na­tion­al se­cu­ri­ty con­cerns.”

On Mon­day the biotech filed no­tice of the Com­mit­tee on For­eign In­vest­ment in the Unit­ed States’ de­ci­sion that it is ex­tend­ing its re­view by 45 days, which puts it on track to make a de­ci­sion by the end of Jan­u­ary — un­less they de­cide to de­lay it again. The biotechs then ex­tend­ed their buy­out pact to the end of De­cem­ber, the lat­est in a long string of de­lays since they an­nounced the deal last June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.